Advanced Oncotherapy PLC Technological update (6608P)

TIDMAVO

RNS Number : 6608P

Advanced Oncotherapy PLC

04 September 2017

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Technological update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, with successful integration of three key elements of the device. The first Side Coupled Drift Tube Linac ("SCDTL") accelerating module has been integrated with the Radiofrequency Quadrupole ("RFQ") and proton source, with functionality of the combination and further proton acceleration confirmed through the measurement of the proton beam through all integrated units.

On 6 March 2017, the Company announced the acceleration of a proton beam through the integrated proton source and RFQ, at the maximum design-anticipated energy of 5 MeV.

The addition of the first SCDTL is significant as:

1. It is the first module in the next group of accelerating structures i.e. the SCDTLs. This successful integration confirms the SCDTL design concept and will facilitate the addition of subsequent SCDTL modules.

2. The proton beam was recorded at 7.5MeV, as expected. This achievement further validates the design, manufacturing and integration of the LIGHT system.

3. As with the RFQ, acceleration of the proton beam at relatively low energies is more challenging than at higher ones; this result is, therefore, an important milestone in LIGHT's development.

When fully integrated with the proton source and RFQ, it is anticipated that four SCDTLs will be capable of producing a proton beam of 37.5MeV.

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said: "All of our tests to generate and accelerate a proton beam have been successful and this represents significant progress in validating the capabilities of the first in the next group of accelerating components. This is another notable achievement for the team in Geneva and paves the way for the integration and validation of subsequent SCDTL modules.

"We can confirm that, following these successful trials, the Company remains on track to build a proton therapy system capable of treating superficial tumours by the end of Q3 2018."

For further information, please contact:

 
                                          www.avoplc.com 
    Advanced Oncotherapy Plc 
  Dr. Michael Sinclair,            Tel: [phone] 
   Executive Chairman 
  Nicolas Serandour, CEO 
 
  Stockdale Securities (Nomad 
   & Joint Broker) 
  Antonio Bossi / David            Tel: [phone] 
   Coaten 
 
  Stifel Nicolaus Europe 
   (Joint Broker) 
  Jonathan Senior / Ben            Tel: [phone] 
   Maddison 
 
  Walbrook PR (Financial        Tel: [phone] or 
   PR & IR)                           [e-mail] 
  Paul McManus / Anna Dunphy     Mob: [phone] / 
                                   Mob: [phone] 
 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLJMITMBIMBFR

(END) Dow Jones Newswires

September 04, 2017 02:00 ET (06:00 GMT)